Bibliography
- PI-SUNYER FX: Medical hazards of obesity. Ann. Intern. Med. (1993) 119:655–660.
- •In depth review of the complications of obesity.
- WATERLOW JC: Research on obesity: a report of a DHSS/MRC Group. Department of Health, HMSO, London, UK (1976).
- BOST L, PRIMATESTA P, DONG W: Antropometricmeasures and children's iron status. In: Health Survey for England 96. Department of Health, HMSO, London, UK (1998).
- THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS: Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity adults. Arch. Intern. Med. (1998) 158:1178–1191.
- GOLDSTEIN DJ: Beneficial health effects of modest weight loss. Int. J. Obes. (1992) 6:397–415.
- •Obese patients who lose only 5% of initial body weight show improvement in cardiovascular risk factors and co-existing disorders.
- LUQUE CA, REY JA: Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. (1999) 33(9):968–978.
- KELLY SM, SHORTHOUSE M, COTTERELL JE et al.: A 3 month double-blind controlled trial of feeding with sucose polyester in human volunteers. Br. J. Nutr. (1998) 80(1):41–49.
- HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized controlled, dose-escalation trial. JAMA (1999) 282(16):1568–1575.
- •Mean weight loss at 6 months was 7.1 kg with the highest dose of leptin.
- ZHI J, MULLIGAN TE, HAUPTMAN JB: Long-term systemic exposure of orlistat, a lipase inhibitor and its metabolites in obese patients./ Cfin. Pharmacol. (1999) 39(1):41–46.
- •Detection of intact orlistat in plasma was sporadic and measurable concentrations were low without evidence of accumulation, which is consistent with minimal absorption.
- Hoffman-La Roche. Data sheet.
- GUERCIOLINI R: Mode of action of orlistat. Int. J. Obes.(1997) 21\(Suppl. 3):512–S23.
- VAN GAAL LF, BROOM JI, ENZI G, TOPLAK H: The Orlistat Dose-Ranging Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur. J. Clin. Pharmacol. (1998) 54:125–132.
- SJOSTROM L, RISSANEN A, ANDERSEN T et al.: Random- ised placebo-controlled trial of orlistat for weight loss and prevention of regain in obese patients. Lancet (1998) 352:167–173.
- ••2-year treatment with orlistat plus diet significantlypromotes weight loss, lessens weight regain and improves some obesity-related disease risk factors.
- DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA (1999) 281:235–242.
- ••2-year treatment with orlistat plus diet significantlypromotes weight loss, lessens weight regain and improves some obesity-related disease risk factors.
- ROSSNER S, SJOSTROM L, NOACK R, MEINDERS AE, NOSEDA G: Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. (2000) 8:49–61.
- ••Orlistat administered for 2 years promotes weight loss andminimises weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure and quality of life.
- HILL JO, HAUPTMAN J, ANDERSON JW et al.: Orlistat, a lipase inhibitor, for weight maintenance after conven-tional dieting: a 1-year study. Am. J. Cfin. Nutr. (1999) 69:1108–1116.
- HENSRUD DD, JENSEN MD: Orlistat. Clin. Perspect. Gastroenterol. (2000) 3(1):50–52.
- •Short review summarising clinical trials with orlistat.
- HOLLANDER PA, ELBEIN SC, HIRSCH IB et al.: Role of orlistat in the treatment of obese patients with Type 2 diabetes. Diabetes Care (1998) 21:1288–1294.
- NAGELE H, PETERSEN B, BONACKER U, RODIGER W: Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur. J. Clin. Pharmacol. (1999) 55:667–669.